Advanced search
Publication Cover
Acta Cardiologica Volume 65, 2010 - Issue 1
Submit an article Journal homepage
6
Views
0
CrossRef citations to date
0
Altmetric
Articles

Influence of drug-eluting stent on inflammation during restenosis in a porcine coronary model

Hailong GeDepartment of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China.
, MD,
Yujie ZhouDepartment of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China.Correspondence[email protected]
, MD,
Hanying MaDepartment of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China.
, MD,
Lei LiuDepartment of Pathology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China.
, MD,
Xiaomin NieDepartment of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China.
, MD,
Zhijian WangDepartment of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China.
, MD &
Fengyun WangResearch Centre of Xiyuan Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China.
, MD show all
Pages 31-35 | Received 15 Jul 2009, Accepted 18 Nov 2009, Published online: 23 May 2017

References

  • Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the develop-ment of new preventive therapies. J Am Coll Cardiol 1991; 17: 758–69.
  • Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explana-tion for recurrent coronary artery stenosis after percuta-neous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369–75.
  • Bae Y, Jeong MH, Ahn YK, Park JH, Cho JG, Park JC, Kang JC, Park OK. Comparison of porcine coronary stent restenosis between MAC (Maximal Arterial Re-Creation) stent and Palmaz-Schatz stent. Korean Circ J 1998; 28: 89–96.
  • Giraldo AA, Esposo OM, Meis JM. Intimal hyperplasia as a cause of restenosis after percutaneous transluminalcoronary angioplasty. Arch Pathol Lab Med 1985; 109: 173–5.
  • Ahn YK, Jeong MH, Kim JW, Kim SH, Cho JH, Cho JG, Park CS, Juhng SW, Park JC, Kang JC. Preventive effects of the heparincoated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999; 48: 324–30.
  • Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regu-lators of the cell cycle. Circulation 1999; 99: 2164–70.
  • Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
  • Gogo PB Jr, Schneider DJ, Watkins MW, Terrien EF, Sobel BE, Dauerman HL. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis 2005; 19: 87–92.
  • Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769–76.
  • Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J2004; 25: 1679–87.
  • Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267–74.
  • Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remod-eling after coronary angioplasty: a serial intravascular ultra-sound study. Circulation 1996; 94: 35–43.
  • Nakatani M, Takeyama Y, Shibata M, Yorozuya M, SuzukiH, Koba S, Katagiri T. Mechanisms of restenosis after coro-nary intervention; difference between plane old balloon angioplasty and stenting. Cardiovasc Pathol 2003, 12: 40–8.
  • Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 1994; 24: 1398–405.
  • Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stent-ing in humans. Circulation 2002; 105: 2974–80.
  • Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004; 44: 1373–85.
  • Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB-and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006; 281: 15099–109.
  • Bu DX, Erl W, de Martin R, Hansson GK, Yan ZQ. IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia. FASEB J 2005; 19: 1293–5.
  • Autieri MV, Yue TL, Ferstein GZ, Ohlstein E.Antisense oligonucleotides to the p65 subunit of NF-kappaB inhibit human vascular smooth muscle cell adherence and prolifer-ation and prevent neointima formation in rat carotid arter-ies. Biochem Biophys Res Commun 1995; 213: 827–36.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.